Imexpharm Achieves Major Growth with Advanced Drug Strategy

Imexpharm is leading the charge in creating innovative, high-value pharmaceuticals, laying a strong foundation for sustainable growth in both local and global markets.

In Vietnam, the rising incidence of non-communicable diseases (NCDs) presents a significant challenge, now comprising over two-thirds of the country’s healthcare burden. As of early 2025, government statistics indicate that more than 12.5 million individuals are living with hypertension, 2.5 million with diabetes, and over 2 million are afflicted with chronic respiratory ailments such as COPD and asthma. Annually, around 125,000 new cancer cases are reported.

This alarming surge in NCDs has intensified the need for advanced medical solutions, compelling pharmaceutical companies to adapt rapidly. In April 2025, Vietnam’s Ministry of Health introduced a groundbreaking Disease Prevention Law project—the first of its kind aimed at enhancing long-term healthcare outcomes by addressing issues such as air pollution, mental health, school health initiatives, and chronic disease management.

The local pharmaceutical industry is undergoing a transformation to tackle these challenges, with a renewed focus on treating conditions like cancer, heart diseases, diabetes, and autoimmune disorders. To align with national healthcare needs and its growth ambitions, Imexpharm is significantly investing in high-tech areas such as biopharmaceuticals, biosimilars, advanced herbal medicines, and leading generic products.

According to SSI Securities, Vietnamese pharmaceutical companies must expand their presence in Group 1 and Group 2 drug markets to lessen dependency on imports. There is a growing demand attributed to an aging population and rising income levels. Firms such as Imexpharm that prioritize research and development are expected to excel as the industry undergoes significant changes.

An additional boost comes from Resolution 68-NQ/TW, which stimulates private sector advancement through scientific innovation and digital transformation. This policy permits businesses to deduct 200% of their R&D expenditures when filing corporate taxes. Imexpharm has already increased its R&D spending by an average of 6% annually, overseeing over 100 active research initiatives.

Among Vietnam’s publicly traded pharmaceutical companies, Imexpharm Pharmaceutical JSC is distinguished by its high-standard production capabilities, boasting 12 EU-GMP certified lines and three factories recognized for EU-GMP compliance. It is the sole domestic entity operating an EU-GMP-certified Betalactam facility for both injectable and oral antibiotics.

Imexpharm’s strategic shift aligns with global trends, as the worldwide pharmaceutical sector is projected to grow at a CAGR of 7.8% through 2026, while Vietnam’s market is expected to see even greater growth, between 10–13%. With its cost advantages, access to raw materials, and robust domestic demand, Vietnam is on track to become a rising pharmaceutical hub in Asia.

A significant goal in Imexpharm’s 2025 strategy is the construction of its new EU-GMP-standard Cat Khanh Pharmaceutical Factory Complex. This facility, with a planned capacity of up to 1.4 billion product units each year (dependent on production phases), will focus on high-value medications for both domestic and overseas markets.

With a strong product portfolio, a comprehensive national distribution network, and a modern management framework, Imexpharm’s leadership has established ambitious goals for 2025, targeting revenues of VND 2,981 billion and a pre-tax profit of VND 493.5 billion, reflecting increases of 18.6% and 22.1%, respectively. Between 2024 and 2030, the company aims for an average annual revenue growth rate of 15%.

Tran Thi Dao, General Director of Imexpharm, stated: “From the beginning, we have emphasized investment in technology and quality. This dedication has positioned us as leaders in EU-GMP-standard pharmaceutical manufacturing for many years. In 2025, our focus will be on three strategic areas: enhancing operational productivity, expanding into new therapeutic fields, and accelerating our growth by diversifying our product offerings and market reach.”